CannTrust’s Medical Cannabis Patient List Grows By 1400%

© 2020 www.B-TV.com. All Rights Reserved.

CannTrust’s  patient base has gone from 2,000 to 30,000 in a year and a half.

CannTrust is bringing more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. Committed to research and innovation, the company can produce high-grade medical cannabis totally free of pesticides.

A Bet on Innovation

The company’s team has joined Apotex, its pharma partner, to innovate and develop products. Furthermore, the company supports patient education about medical cannabis, and has launched a compassionate use program to support patients with financial needs.

State-of-the-art cannabis production facility

The company runs a 50,000-square foot hydroponic facility that enables them to control the whole process as well as the results. So, they get pharmaceutical-grade control and can test products at any point. This, combined with a patient-oriented strategy, ensures the company is delivering quality products and superior service to customers. CannTrust is expanding its production capacity with a 430,000 square foot greenhouse in the heart of the Niagara region. Designed and engineered to guarantee a continuous supply of high quality, standardized products, the facility will be the first of its kind in Canada and one of the largest in North America.

Testing technology and Canadian license

A laboratory onsite with advanced technology and equipment provides CannTrust the ability to test and research on the medical use of cannabis.  And above all, to develop and rigorously test products to deliver consistent  high-quality products. CannTrust has been granted a Section 9 License by Health Canada under the Narcotic Control Regulations. This allows the company to expand product development and research to include pharmaceuticals to better serve patients and customers. For more information on CannTrust (TRST.CN)

Request Investor Info